Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 29;41(3):67.
doi: 10.1007/s12032-023-02281-6.

Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment

Nathan A Haines  1   2 , Mia G Fowler  2 , Benjamin G Zeh  1   2 , Carter B Kriete  2 , Qian Bai  2 , Mark R Wakefield  2   3 , Yujiang Fang  4   5   6
Affiliations
Review

Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment

Nathan A Haines et al. Med Oncol. .

Abstract

Ovarian cancer is a prominent cancer worldwide with a relatively low survival rate for women diagnosed. Many individuals are diagnosed in the late stage of the disease and are prescribed a wide variety of treatment options. Current treatment options are primarily a combination of surgery and chemotherapy as well as a new but promising treatment involving immunotherapy. Nevertheless, contemporary therapeutic modalities exhibit a discernible lag in advancement when compared with the strides achieved in recent years in the context of other malignancies. Moreover, many surgery and chemotherapy options have a high risk for recurrence due to the late-stage diagnosis. Therefore, there is a necessity to further treatment options. There have been many new advancements in the field of immunotherapy. Immunotherapy has been approved for 16 various types of cancers and has shown significant treatment potential in many other cancers as well. Researchers have also found many promising outlooks for immunotherapy as a treatment for ovarian cancer. This review summarizes many of the new advancements in immunotherapy treatment options and could potentially offer valuable insights to gynecologists aimed at enhancing the efficacy of their treatment approaches for patients diagnosed with ovarian cancer.

Keywords: Cytokine; Immunotherapy; Interleukins; Ovarian cancer.

PubMed Disclaimer

References

    1. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. https://doi.org/10.3390/ijms20040952 . - DOI - PubMed - PMC
    1. Lele S. Ovarian cancer. Brisbane City: Exon Publications; 2022. - DOI
    1. Guo X, Zhao G. Establishment and verification of logistic regression model for qualitative diagnosis of ovarian cancer based on MRI and ultrasound signs. Comput Math Methods Med. 2022;2022:7531371. https://doi.org/10.1155/2022/7531371 . - DOI - PubMed - PMC
    1. Staicu CE, Predescu DV, Rusu CM, Radu BM, Cretoiu D, Suciu N, Crețoiu SM, Voinea SC. Role of microRNAs as clinical cancer biomarkers for ovarian cancer: a short overview. Cells. 2020;9(1):169. https://doi.org/10.3390/cells9010169 . - DOI - PubMed - PMC
    1. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–6. https://doi.org/10.1016/j.soncn.2019.02.001 . - DOI - PubMed

LinkOut - more resources